Shaanxi Kanghui Pharmaceutical (603139. SH) intends to promote a restricted stock incentive plan for 2026.
Kanghui shares (603139.SH) disclosed the 2026 restricted stock incentive plan (draft), with proposed restricted stock grants not exceeding 7.99 million shares, accounting for 8% of the total share capital of the company at the time of the announcement of the incentive plan draft. The total number of incentive recipients is not more than 80 people, with a grant price of 20 yuan per share.
Shaanxi Kanghui Pharmaceutical (603139.SH) disclosed the draft of the restricted stock incentive plan for 2026, proposing to grant a maximum of 7.99 million restricted stocks, accounting for 8% of the total share capital of the company at the time of the announcement of the draft plan. The total number of incentive recipients is not more than 80 people, with a grant price of 20 yuan per share.
Related Articles
HANXBIO-B (03378) spent 631,200 Hong Kong dollars to repurchase 22,400 shares on May 27th.
LIANLIAN (02598) spent HK$1.6431 million on May 27 to repurchase 311,000 shares.
Xingyuan Environment Technology's subsidiary, Xing'ao Environment, signs debt transfer agreement.
HANXBIO-B (03378) spent 631,200 Hong Kong dollars to repurchase 22,400 shares on May 27th.
LIANLIAN (02598) spent HK$1.6431 million on May 27 to repurchase 311,000 shares.
Xingyuan Environment Technology's subsidiary, Xing'ao Environment, signs debt transfer agreement.
